| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.21 | 0.2 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.071 | 0.2 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.2 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.2 |